Johnson & Johnson's Outlook Clouded By $2 Billion Headwind

Johnson & Johnson (NYSE:JNJ) is set to release its second-quarter earnings on Wednesday, July 16. According to Benzinga Pro data, analysts estimate adjusted earnings of $2.68 per share and sales of $22.85 billion.

While overall estimates for 2025 and beyond show only slight increases, investor attention is expected to heavily center on the company’s updated 2025 guidance, the evolving impact of tariffs and biosimilars, and the progress of its pipeline and recent product launches.

Adding to the pre-earnings anticipation, Bank of America Securities (BofA) has already updated its revenue estimates for J&J for 2025 and beyond ahead of second-quarter earnings.

Also Read: FDA Issues Early Alert For Johnson & Johnson’s Abiomed Heart Pump Controllers

BofA analyst Tim Anderson notably highlighted that the major focus is expected to be updated 2025 guidance, tariff impact, biosimilar impact, and pipeline and launch progress.

BofA itself slightly increased its second-quarter 2025 revenue and ...